Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications

Sherif, Eman M.; Abdelmaksoud, Abeer A.; Youssef, Omneya Ibrahim; Salah, Nouran Yousef; Khater, Ola Khaled Mohamed

doi:10.1016/j.jdiacomp.2019.06.001

Cited by 13 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that suPAR was positively correlated with diabetes duration. This data is consistent with the results published in prior studies [7,30,31]. Another finding is the negative correlation between serum suPAR levels and ACEI/ARBs treatment, but the cross-sectional design of the study does not allow a remark regarding the causative renoprotective effect of this class of drugs.…”

Section: Discussionsupporting

confidence: 91%

Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy

Lupusoru

Ailincăi

Sorohan

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy

Lupusoru

Ailincăi

Sorohan

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…Of the 53 studies, 37 reported obesity and/or overweight prevalence in their respective samples [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , with the prevalence of obesity ranging from 0·3% to 50% These studies consistently found a higher prevalence of elevated BP and/or hypertension in participants with obesity, overweight, or central obesity. A case-control study where authors compared prevalence of hypertension in children with and with out obesity found that only the children in the obesity group had hypertension (25%), and this group had significantly more cases of elevated BP than the non-obesity group (19·4% vs 6·5%) (Chedjou-Nono et al [68] ).…”

Section: Resultsmentioning

confidence: 99%

“…Of the 53 studies included in the systematic review, in total 41 were included for meta-analysis for at least one outcome (hypertension, elevated BP, or both combined). Reasons for exclusion of the remaining 12 articles were as follows: high risk of bias (Masocha et al [50] ), study from the same database included (Nqweniso et al [73] , Schoenbuchner et al [74] , Matjuda et al [46] , Hassana et al [36] , Nkwana et al [49] ), lack of aggregated data for systolic/diastolic hypertension (Sherif et al [38] , Elseifi et al [35] , Musa et al [33] , Gomwe et al [75] ), and lack of extractable raw numerator or denominator data (Raphadu et al [51] , Chedjou-Nono et al [68] ) ( Figure 1 ). This resulted in 38 studies, 24 studies, and 27 studies included for hypertension, elevated BP, and combined hypertension/elevated BP, respectively.…”

Section: Resultsmentioning

confidence: 99%

Paediatric Hypertension in Africa: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Background The burden of cardiovascular disease (CVD) and hypertension is rapidly increasing in low- and middle-income countries. This is evident not only in adults, but also in children. Recent estimates of prevalence in children are lacking, particularly in Africa. As such, we conducted a systematic review and meta-analysis to provide updated estimates of paediatric hypertension in Africa. Methods We searched PubMed and EBSCO to identify articles published from January 2017 to November 2020. Studies were assessed for quality. We combined results for meta-analyses using a random effects model (Freeman-Tukey arcsine transformation). Heterogeneity was quantified using the I 2 statistic. Findings In the narrative synthesis of 53 studies, publication bias was low for 28, moderate for 24, and high for one study. Hypertension prevalence ranged substantially (0·2%-38·9%). Meta-analysis included 41 studies resulting in data on 52918 participants aged 3 to 19 years from ten countries. The pooled prevalence for hypertension (systolic/diastolic BP≥95th percentile) was 7·45% (95%CI 5·30-9·92, I 2 =98.96%), elevated blood pressure (BP, systolic/diastolic BP≥90th percentile and <95th percentile) 11·38% (95%CI 7·94-15·33, I 2 =98.97%) and combined hypertension/elevated BP 21·74% (95%CI 15·5-28·69, I 2 =99.48%). Participants categorized as overweight/with obesity had a higher prevalence of hypertension (18·5% [95%CI 10·2-28·5]) than those categorized as underweight/normal (1·0% [95%CI 0·1-2·6], 4·8% [95%CI 2·9-7·1], p<0·001). There were significant differences in hypertension prevalence when comparing BP measurement methods and classification guidelines. Interpretation Compared to a previous systematic review conducted in 2017, this study suggests a continued increase in prevalence of paediatric hypertension in Africa, and highlights the potential role of increasing overweight/obesity. Funding This research was funded in part by the Wellcome Trust [Grant number:214082/Z/18/Z]. LJW and SAN are supported by the DSI-NRF Centre of Human Development at the University of the Witwatersrand.

show abstract

“…[26] However, the levels of soluble uPAR between healthy subjects and T2DM patients without nephropathy showed no significant difference. However, a large bundle of studies showed soluble uPAR is associated with various complications of T2DM, such as nephropathy, retinopathy, peripheral artery disease, and cardiovascular events [26,27,28,29]. Nonetheless, whether deficiency of uPA and high levels of uPAR synergistically contribute to insulin secretion impairment and complications of T2DM needs further explorations in the future.…”

Section: Resultsmentioning

confidence: 99%

Deficiency of Urokinase Plasminogen Activator May Impair β Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus

Chang

et al. 2019

Molecules

View full text Add to dashboard Cite

Background: The relationship between urokinase-type plasminogen activator (uPA) and the development of type 2 diabetes mellitus (T2DM) was investigated in the study by using mice and cell models, as well as patients with T2DM. Methods: In mice models, wild-type and uPA knockout (uPA-/-) BALB/c mice were used for induction of T2DM. In cell models, insulin secretion rate and β cell proliferation were assessed in normal and high glucose after treating uPA siRNA, uPA, or anti-uPA antibody. In our clinical study, patients with T2DM received an oral glucose-tolerance test, and the relationship between uPA and insulin secretion was assessed. Results: Insulin particles and insulin secretion were mildly restored one month after induction in wild-type mice, but not in uPA-/- mice. In cell models, insulin secretion rate and cell proliferation declined in high glucose after uPA silencing either by siRNA or by anti-uPA antibody. After treatment with uPA, β cell proliferation increased in normal glucose. In clinical study, patients with T2DM and higher uPA levels had better ability of insulin secretion than those with lower uPA levels. Conclusion: uPA may play a substantial role in insulin secretion, β cell regeneration, and progressive development of T2DM. Supplementation of uPA might be a novel approach for prevention and treatment of T2DM in the future.

show abstract

Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications

Cited by 13 publications

References 19 publications

Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy

Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy

Paediatric Hypertension in Africa: A Systematic Review and Meta-Analysis

Deficiency of Urokinase Plasminogen Activator May Impair β Cells Regeneration and Insulin Secretion in Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About